{"id":"W4405046844","doi":"10.1182/blood-2024-206096","title":"R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Genentech; Sierra Oncology; Incyte; Swedish Orphan Biovitrum; Astex Pharmaceuticals; Jazz Pharmaceuticals; MorphoSys; Celgene; Bristol-Myers Squibb; Helsinn; Servier; Amgen","keywords":"Medicine; Internal medicine; Refractory (planetary science); Myelodysplastic syndromes; Lenalidomide; Oncology; Gastroenterology; Bone marrow; Biology; Multiple myeloma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007865072,0.0007562004,0.001025449,0.0001957618,0.0001851488,0.0003987894,0.0004232642,0.0005280899,0.001668916],"category_scores_gemma":[0.0004073814,0.000296188,0.0006684809,0.0001874094,0.0004031348,0.000363589,0.0002092335,0.001522488,0.0005088964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004261746,"about_ca_system_score_gemma":0.0006648622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005406118,"about_ca_topic_score_gemma":0.001643633,"domain_scores_codex":[0.9998339,0.00007960119,0.00001313143,0.00002635984,0.00001862818,0.0000283898],"domain_scores_gemma":[0.9997759,0.00004735523,0.00005108327,0.00001732241,0.00001528236,0.00009300919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4824758,0.05786281,0.01787359,0.001811291,0.001786095,0.00069488,0.0005264443,0.005518913,0.1357011,0.0002564951,0.00544383,0.2900487],"study_design_scores_gemma":[0.40122,0.540741,0.03924035,0.00008116631,0.0009129956,0.0008363351,0.0001067896,0.002567347,0.009931892,0.0002234125,0.004096894,0.00004169068],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958359,0.001909963,0.0003253793,0.0002185497,0.00002508216,0.0004951345,0.0003964645,0.00006266549,0.0007308327],"genre_scores_gemma":[0.9943738,0.00155104,0.001093394,0.0004105394,0.00005010134,0.0004405087,0.0009592872,0.00001545022,0.001105763],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001668916,"threshold_uncertainty_score":0.005583107,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01538506772038575,"score_gpt":0.2898760883223052,"score_spread":0.2744910206019194,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}